House Democrats are on the cusp of passing two major pieces of Biden’s agenda Friday, but Medicare drug price negotiations — once the centerpiece of the Build Back Better Act’s revenue stream — has…
Say hello to yet two more biotechs that jumped on a 2021 IPO this week. German firm Evotec SE debuted a downsized IPO in the US yesterday — pricing at $21.75 per ADS share and $43.50 for a share on…
The US government’s $1.8 billion investment into Novavax’s Covid-19 vaccine may soon pay off as the company floated some positive comments around the issues surrounding the manufacturing of its…
McKinsey is under fire again, this time from the House Oversight Committee, which is digging into the consulting firm’s close ties to the FDA while working simultaneously to promote opioids and find…
Bit.bio CEO Mark Kotter says the last major revolution in biopharma occurred around the 1980s, when antibodies — or, as some called them, anticancer ‘magic bullets’ — opened up the door for new…
Recouping from a series of setbacks for its gene therapy business, bluebird bio successfully bisected itself earlier this week as part of a big rebrand around genetic disease. Now, with its future…
As Nitrome Biosciences — a biotech founded in 2017 to focus on a class of enzymes called nitrases — rebrands to Nitrase Therapeutics, the company is also bringing on a new CEO: Pierre Beaurang. In…
Despite a very late line approval for its TKI drug last year, Deciphera has had its eyes set on cracking into earlier patients with GI tumors — a possibility investors cheered. But that door has now…
Pfizer on Friday unveiled statistically significant efficacy data for its potential Covid-19 pill among people who haven’t been hospitalized with the virus. The data will likely lead to a quick EUA…
The global trial evaluated the long-term results of the medtech giant’s first- and second-generation TAVR systems, under its CoreValve and Evolut R platforms. The results illustrate the long-term…
